A dream life post COVID will soon be a reality
about us
At Coronavax, we are applying the principles of Immuno-Oncology to treat long covid so that you can have a pain free life
about long covid
What?
Long COVID is a condition where COVID-19 symptoms persist long after the initial infection has cleared. These symptoms, lasting for months to years, can significantly impact daily life.
Who?
An estimated 1 in 13 adults in the U.S. (7.5%) have Long COVID symptoms. At least 65M persons worldwide, about 30-75% of recovering patients, are affected. Each new infection can increase the risk of developing Long COVID.
Why?
Harvard University estimates that the total economic cost of long COVID is $3.7 trillion. That’s $11,000 per capita or 17% of the 2019 gross domestic product (GDP).
Our story so far
Our team
Founder's Note
Hey everyone,
I’m Bruce, CEO here at Coronavax.
Long COVID affects an estimated 100 million people, leaving many with few treatment options and a quality of life often worse than that of advanced cancer patients. A consensus is emerging that Long COVID is an inflammatory condition caused by the immune system's failure to completely eliminate the virus. This issue is made worse by the virus hiding in mucosal and fatty tissues, which are notoriously hard for drugs to reach.
Drawing inspiration from cancer immunotherapy, which has successfully cured thousands by stimulating the immune system, we're bringing this revolutionary science to Long COVID. At Coronavax, we focus on mucosal immunity to target and eliminate the virus without causing excessive inflammation.
Just as immunotherapy has transformed cancer treatment, we aim to do the same for Long COVID. We believe in the potential of our approach and are dedicated to making a difference.
Together, we can bring hope and healing to millions. Join us.
Best,
Bruce Lyday
FAQs
Join us in fighting Long Covid
We are looking for investors to help fund the mission.